Recent Quotes (30 days)

You have no recent quotes
chg | %

Pfizer Inc. news

   Watch this stock
Showing stories 1 - 10 of about 242   

Articles published

PFE 35.97 -0.02 (-0.06%)
price chart
Pfizer files suit against J&J over Remicade contracts
(Reuters) - Drugmaker Pfizer Inc (PFE.N) on Wednesday filed a lawsuit against Johnson & Johnson (JNJ.N), saying its rival's contracts with health insurers for blockbuster rheumatoid arthritis drug, Remicade, were anticompetitive and blocked sales of ...
Pfizer Sues J&J, Accuses it of Preventing Inflectra Uptake  Nasdaq
Pfizer's stock jumps to 13-month high to lead Dow gainers after analyst upgrade
Shares of Pfizer Inc. PFE, +1.52% surged 1.3% in morning trade Wednesday toward a 13-month high, after the drug maker was upgraded at Morgan Stanley, which cited valuation following "a long period of middling performance.
Pfizer Should Outperform, Morgan Stanley Upgrades  Benzinga
Are Investors Buying or Selling Pfizer Inc. (PFE), and What Should You Do?  NY Stock News
Better Buy: Pfizer Inc. vs. Bristol-Myers Squibb
Pfizer's pipeline includes 10 programs awaiting regulatory approval and 32 late-stage programs. The company also has another 17 phase 2 programs.
Recent Buy: Pfizer Inc.
I will be explaining my fourth buy of the month of August. Share prices of Pfizer Inc. (PFE) have been hovering between $29.00 and $36.00 for the past two and half years.
Pfizer, Inc. (NYSE:PFE) Stake Decreased by WINTON GROUP Ltd  The Ledger Gazette
Pfizer Inc. (PFE) Moves Higher on Volume Spike for September 14  Equities.com
Why to Keeping Eye on Praxair, Inc. (PX), Pfizer Inc. (PFE)?
Pfizer Inc. (NYSE:PFE), at its latest closing price of $35.99, it has a price-to-book ratio of 0.00, compared to an industry average at 0.61.
Pfizer Inc. (PFE) Closes 0.06% Down on the Day for September 21
Shares of Pfizer Inc. (PFE) ended the trading day Thursday at $35.97, representing a move of -0.06%, or $0.02 per share, on volume of 15.53 million shares.
Altfest LJ & Co. Inc. Grows Holdings in Pfizer, Inc. (PFE)  The Ledger Gazette
Effectively hedging the stocks in today's share market: Pfizer Inc ...  The News Journal
Pfizer, Astellas prostate cancer drug promising in late-stage trial
(Reuters) - Pfizer Inc and Japan's Astellas Pharma Inc said on Thursday their blockbuster prostate cancer drug met the main goal of a key study that tested it for treating the disease in its early stages.
Pfizer shares rise 1.4% after news of positive late-stage cancer trial  MarketWatch
Pfizer, Astellas eye wider market for prostate cancer drug  BioPharma Dive
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare ...
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to listen to a discussion with Liz Barrett, Global President, Oncology, and Chris Boshoff, Senior Vice President and Head, Immuno-Oncology, Early Development and ...
FDA sends damning warning letter to Pfizer after misfiring EpiPens linked to ...
The US Food and Drug Administration has sent a damning warning letter to drug giant Pfizer Inc (NYSE:PFE) after it received “hundreds of complaints” that the anti-allergy EpiPen device misfired “during life-threatening emergencies”.
FDA Warns Pfizer's Meridian Unit on EpiPen Oversight, Quality Issues  Wall Street Journal (subscription)
Pfizer's EpiPen manufacturer warned by FDA  BioPharma Dive
UPDATE 1-Pfizer files suit against J&J over Remicade contracts
Sept 20 (Reuters) - Drugmaker Pfizer Inc on Wednesday filed a lawsuit against Johnson & Johnson, saying its rival's contracts with health insurers for blockbuster rheumatoid arthritis drug, Remicade, were anticompetitive and blocked sales of Pfizer's ...